Erba Transasia Unveils Advanced Haematology Analyzer in Chennai

Chennai: Erba Transasia Group, India’s leading In-vitro Diagnostic (IVD) company, launched its latest innovation, the Erba H7100 Haematology Analyzer, during a clinical symposium held in Chennai. Themed “High-End Haematology Solutions for Laboratory Challenges,” the event highlighted the urgent need for advanced diagnostic tools in Tamil Nadu.

Prominent healthcare experts, including Prof. Dr. C.N. Srinivas from Kauvery Hospital and Dr. V. Chitrasree from The Madras Medical Mission, emphasized the rising prevalence of blood disorders among adolescents and young adults. They pointed out the growing role of advanced diagnostics in addressing conditions such as anaemia, thalassemia, and blood cancers.

The Erba H7100, powered by fluorescence flow cytometry technology, offers an impressive 70-parameter range, including Reticulocytes and Immature Platelet Fraction (IPF). Its Mentzer Index feature aids in differentiating between Iron Deficiency Anemia (IDA) and Beta Thalassemia, while its Optical Platelet (Plt-O) function ensures accurate platelet counts, addressing pseudo-thrombocytopenia concerns.

Suresh Vazirani, Founder Chairman of Erba Transasia Group, stated, “Our innovative H7100 analyzer is designed to bridge diagnostic gaps, providing cost-effective and reliable solutions for medium to large laboratories.”

The device also tackles diagnostic challenges in underserved communities, offering critical support for hereditary conditions like thalassemia. According to Vijay Kumar, Country Head at Transasia Bio-Medicals, the H7100 is tailored to enhance lab efficiency while delivering accurate results, empowering healthcare providers with better tools for patient care.

With its innovative features and robust technology, the Erba H7100 is set to redefine haematology diagnostics in Tamil Nadu, paving the way for improved healthcare outcomes across diverse patient populations.